This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Think Research Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Think Research hat ein Gesamteigenkapital von CA$28.0M und eine Gesamtverschuldung von CA$41.8M, was einen Verschuldungsgrad von 149.2% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CA$114.7M bzw. CA$86.7M.

Wichtige Informationen

149.2%

Verhältnis von Schulden zu Eigenkapital

CA$41.76m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CA$3.75m
Eigenkapital	CA$27.99m
Gesamtverbindlichkeiten	CA$86.67m
Gesamtvermögen	CA$114.66m

Jüngste Berichte zur Finanzlage

Is Think Research (CVE:THNK) Using Debt In A Risky Way?

Feb 10

Recent updates

Is Think Research (CVE:THNK) Using Debt In A Risky Way?

Feb 10

Little Excitement Around Think Research Corporation's (CVE:THNK) Revenues As Shares Take 28% Pounding

Dec 18

Why Investors Shouldn't Be Surprised By Think Research Corporation's (CVE:THNK) 26% Share Price Plunge

Sep 06

Think Research Corporation (CVE:THNK) Shares Could Be 48% Below Their Intrinsic Value Estimate

Feb 28

Analysts Have Been Trimming Their Think Research Corporation (CVE:THNK) Price Target After Its Latest Report

Dec 01

Analysts Expect Breakeven For Think Research Corporation (CVE:THNK) Before Long

Mar 30

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: THNKDie kurzfristigen Aktiva des Unternehmens (CA$19.4M) decken seine kurzfristigen Passiva (CA$59.8M) nicht.

Langfristige Verbindlichkeiten: THNKDie kurzfristigen Vermögenswerte des Unternehmens (CA$19.4M) decken seine langfristigen Verbindlichkeiten (CA$26.9M) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: THNKDie Nettoverschuldung im Verhältnis zum Eigenkapital (135.8%) wird als hoch angesehen.

Schulden abbauen: THNK hatte vor 5 Jahren ein negatives Eigenkapital, ist jetzt aber positiv und hat sich somit verbessert.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: THNK auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: THNK verfügt über eine ausreichende Liquiditätsreserve für 2.8 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 14 % pro Jahr wächst.

This company listing is no longer active

Think Research Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Think Research (CVE:THNK) Using Debt In A Risky Way?

Recent updates

Healwell AI Inc. (TSX:AIDX) completed the acquisition of Bio Pharma Services Inc. from Think Research Corporation for CAD 15 million.

Healwell AI Inc. (TSX:AIDX) agreed to acquire 100% stake in Bio Pharma Services Inc. from Think Research Corporation for CAD 14.4 million.

Healwell AI Inc. (TSX:AIDX) agreed to acquire 100% stake in Bio Pharma Services Inc. from Think Research Corporation for CAD 14.4 million.

Beedie Capital completed the acquisition of remaining 96.27551% stake in Think Research Corporation (TSXV : THNK) from shareholders for CAD 17.57 million.

Beedie Capital completed the acquisition of remaining 96.27551% stake in Think Research Corporation (TSXV : THNK) from shareholders for CAD 17.57 million.

Think Research Corporation, Annual General Meeting, Apr 04, 2024

Beedie Capital entered into an arrangement agreement to acquire remaining 96.27551% stake in Think Research Corporation (TSXV : THNK) from shareholders for CAD 25.58 million.

Beedie Capital entered into an arrangement agreement to acquire remaining 96.27551% stake in Think Research Corporation (TSXV : THNK) from shareholders for CAD 25.58 million.

Is Think Research (CVE:THNK) Using Debt In A Risky Way?

New major risk - Market cap size

Insufficient new directors

New major risk - Share price stability

Little Excitement Around Think Research Corporation's (CVE:THNK) Revenues As Shares Take 28% Pounding

New major risk - Market cap size

New minor risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Think Research Corporation to Report Q3, 2023 Results on Nov 27, 2023

Think Research Corporation Appoints Jeffrey Orridge to Its Board of Directors

Why Investors Shouldn't Be Surprised By Think Research Corporation's (CVE:THNK) 26% Share Price Plunge

Price target decreased by 14% to CA$0.73

Second quarter 2023 earnings: EPS exceeds analyst expectations

Think Research Corporation to Report Q2, 2023 Results on Aug 29, 2023

Think Research Corporation Announces Bridge Loan

First quarter 2023 earnings released: CA$0.047 loss per share (vs CA$0.11 loss in 1Q 2022)

Think Research Corporation, Annual General Meeting, Aug 11, 2023

Think Research Corporation to Report Q1, 2023 Results on May 29, 2023

Consensus EPS estimates fall by 17%

Full year 2022 earnings: EPS misses analyst expectations

Think Research Corporation (CVE:THNK) Shares Could Be 48% Below Their Intrinsic Value Estimate

Analysts Have Been Trimming Their Think Research Corporation (CVE:THNK) Price Target After Its Latest Report

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Think Research Corporation to Report Q3, 2022 Results on Nov 28, 2022

High number of new directors

Think Research Appoints John Hayes as Permanent Chief Financial Officer

Consensus revenue estimates fall by 11%

Price target decreased to CA$1.25

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Think Research Corporation to Report Q2, 2022 Results on Aug 29, 2022

Consensus forecasts updated

Think Research Corporation, Annual General Meeting, Aug 02, 2022

Think Research Corporation to Report Q1, 2022 Results on May 30, 2022

Now 26% undervalued after recent price drop

Now 24% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

High number of new directors

Think Research Corporation announced that it expects to receive CAD 25 million in funding from Beedie Capital

Price target decreased to CA$3.08

Think Research Corporation Announces Executive Changes

Think Research Launches Electronic Data Capture System for its Clinical Research Phase 1 Business, Bio Pharma Services Inc

Think Research Corporation Attests to Vendor Verification for Virtual Care in Ontario

CEO & Director recently sold CA$86k worth of stock

Consensus forecasts updated

High number of new directors

Chief Operating Officer Riyaz Lalani has left the company

Think Research Corporation (TSXV:THNK) completed the acquisition of BioPharma Services Inc. from Mahy Investments Ltd., Moske Investments Ltd., N & M Medical Enterprises Inc., Ola Kassim Medicine Professional Corporation and Kashima International Inc. for CAD 43.3 million.

Consensus revenue estimates increase to CA$45.4m

Think Research Corporation (TSXV:THNK) entered into a definitive agreement to acquire BioPharma Services Inc. for CAD 44.6 million.

Think Research Corporation Sees 140% Year-Over-Year Growth for eForms Electronic Data Capture Software in U.S. Post-Acute Care Market

Think Research Corporation Provides Earnings Guidance for the First Quarter Ended March 31, 2021

Analysts Expect Breakeven For Think Research Corporation (CVE:THNK) Before Long

Think Research Partners with Carerx to Deliver Virtualcare Telemedicine Software in Retirement Homes Across Canada

CareRx Corporation and Think Research Corporation Announces Their Canada-Wide Partnership to Deliver Virtual Healthcare to Seniors

Full year 2020 earnings released: CA$0.40 loss per share (vs CA$0.59 loss in FY 2019)

Think Research Corporation (TSXV:THNK) completed the acquisition of Clinic 360 for CAD 5.5 million.

Think Research Corporation (TSXV:THNK) acquired AirMed Trials Inc. for CAD 0.75 million.

Think Research Corporation (TSXV:THNK) entered into a share purchase agreement to acquire mdBriefCase Inc. from PCP GP, L.P. ,Jason Flowerday and others for CAD 24.9 million

Think Research Announces Appointment of Dr. Eric Hoskins to Board of Directors

Think Research Corporation (TSXV:THNK) agreed to acquire Clinic 360 for CAD 5.8 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen